Financial Statements

TG Therapeutics, Inc. (TGTX)


-0.21 (-2.34%)
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers are in thousands , Years are calendar years not fiscal years

Retained Earning Schedule

Year 2022 2021 2020 2019 2018
Retained Earnings (Previous Year) -1,329-981-701-528-
Net Income -204-356-286-179-173
Stock Dividends 5766-355
Dividend Paid -----
Retained Earnings -1,527-1,329-981-701-528

PPE Schedule

Year 2022 2021 2020 2019 2018
Gross PPE 1112123-
Annual Depreciation -0-0093
Capital Expenditure -0-0-0-0-0
Net PPE 111112123

Intangible and Goodwill Schedule

Year 2022 2021 2020 2019 2018
Intangible and Goodwill (Previous Year) -1111
New Purchases -31-30-67-56-107
Intangible and Goodwill 11111

TG Therapeutics, Inc. income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes TG Therapeutics, Inc. FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.